Nyxoah SA
NYXH5.020USD
+0.030+0.60%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
187.93MMarket Cap
LossP/E TTM
More Details of Nyxoah SA Company
Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
Nyxoah SA Info
Ticker SymbolNYXH
Company nameNyxoah SA
IPO dateSep 18, 2020
CEOMr. Olivier Taelman
Number of employees- -
Security typeOrdinary Share
Fiscal year-endSep 18
AddressRue Edouard Belin 12
CityMONT-SAINT-GUIBERT
Stock exchangeEuronext Brussels
CountryBelgium
Postal code1435
Phone3226121755
Websitehttps://www.nyxoah.com/
Ticker SymbolNYXH
IPO dateSep 18, 2020
CEOMr. Olivier Taelman
Company Executives of Nyxoah SA
Name
Name/Position
Position
Shareholding
Change
Mr. Robert Taub
Mr. Robert Taub
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
3.98M
+17.27%
Mr. John Landry
Mr. John Landry
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Maurits S. Boon
Dr. Maurits S. Boon
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Loic Moreau
Mr. Loic Moreau
President - International
President - International
--
--
Mr. Olivier Taelman
Mr. Olivier Taelman
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Virginia Kirby
Ms. Virginia Kirby
Independent Director
Independent Director
--
--
Mr. Christoph Eigenmann
Mr. Christoph Eigenmann
Chief Commercial Officer
Chief Commercial Officer
--
--
Ms. Rita F. Johnson-Mills
Ms. Rita F. Johnson-Mills
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Pierre Gianello, M.D.
Dr. Pierre Gianello, M.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Robert Taub
Mr. Robert Taub
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
3.98M
+17.27%
Mr. John Landry
Mr. John Landry
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Maurits S. Boon
Dr. Maurits S. Boon
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Loic Moreau
Mr. Loic Moreau
President - International
President - International
--
--
Mr. Olivier Taelman
Mr. Olivier Taelman
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Virginia Kirby
Ms. Virginia Kirby
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Sep 24
Updated: Wed, Sep 24
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cochlear Limited
15.05%
Taub (Robert)
10.62%
Monden (Anneliese)
7.86%
Gilde Healthcare Partners B.V.
7.85%
ResMed Inc
4.62%
Other
54.01%
Shareholders
Shareholders
Proportion
Cochlear Limited
15.05%
Taub (Robert)
10.62%
Monden (Anneliese)
7.86%
Gilde Healthcare Partners B.V.
7.85%
ResMed Inc
4.62%
Other
54.01%
Shareholder Types
Shareholders
Proportion
Individual Investor
22.07%
Corporation
19.66%
Venture Capital
7.85%
Investment Advisor/Hedge Fund
6.99%
Investment Advisor
6.16%
Hedge Fund
0.78%
Research Firm
0.16%
Other
36.33%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
74
8.21M
21.94%
-2.04M
2025Q2
69
25.16M
67.22%
-3.01M
2025Q1
70
26.40M
70.53%
-2.65M
2024Q4
73
25.60M
68.47%
-1.01M
2024Q3
72
23.51M
71.46%
-828.78K
2024Q2
72
23.54M
72.39%
-1.11M
2024Q1
64
20.89M
72.68%
+374.51K
2023Q4
59
21.08M
73.36%
-418.05K
2023Q3
66
19.86M
69.10%
-2.56M
2023Q2
66
20.66M
78.20%
+1.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cochlear Limited
5.63M
15.05%
--
--
Aug 29, 2025
Taub (Robert)
3.98M
10.62%
+585.48K
+17.27%
Dec 31, 2024
Monden (Anneliese)
2.94M
7.86%
--
--
Dec 31, 2024
Gilde Healthcare Partners B.V.
2.94M
7.85%
--
--
Dec 31, 2024
ResMed Inc
1.73M
4.62%
--
--
Dec 31, 2024
Hambrecht (Jürgen)
1.34M
3.59%
--
--
Dec 31, 2024
Vestal Point Capital, LP
1.11M
2.98%
-288.43K
-20.57%
Sep 24, 2025
BNP Paribas Asset Management Belgium S.A.
742.38K
1.98%
--
--
Aug 31, 2025
BlackRock Financial Management, Inc.
683.64K
1.83%
-281.93K
-29.20%
Jun 30, 2025
Fidelity Management & Research Company LLC
679.59K
1.82%
-431.65K
-38.84%
Jun 30, 2025
View more
Related ETFs
Updated: 22 hours ago
Updated: 22 hours ago
Name
Proportion
iShares Health Innovation Active ETF
0.07%
Avantis International Equity ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
SPDR Portfolio Europe ETF
0%
DFA Dimensional International Small Cap ETF
0%
Avantis International Small Cap Equity ETF
0%
iShares Health Innovation Active ETF
Proportion0.07%
Avantis International Equity ETF
Proportion0%
DFA Dimensional International Core Equity 2 ETF
Proportion0%
SPDR Portfolio Europe ETF
Proportion0%
DFA Dimensional International Small Cap ETF
Proportion0%
Avantis International Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
